Skip to main content
. 2015 Jul 7;171(3):344–354. doi: 10.1111/bjh.13582

Figure 2.

Figure 2

Time‐to‐next therapy (TTNT) and overall survival (OS) with VTD and VTDC. (A) TTNT. (B) OS. CI: confidence interval; HR: hazard ratio; NE: not estimatable; VTD, bortezomib‐thalidomide‐dexamethasone; VTDC, bortezomib‐thalidomide‐dexamethasone plus cyclophosphamide.